

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Sir:

Applicant filed a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 on 7 August 2006. The RCE included a substitute specification. While the paragraph numbering on the marked-up copy of the substitute specification was correct, the paragraph numbering on the “clean” copy was out of register. The present supplemental amendment corrects the informality.

Applicant requests entry of the attached corrected “clean” copy of the substitute specification (without abstract). The paragraph numbering in this corrected version matches the numbering in the marked-up version filed on 7 August. The corrected substitute specification is otherwise identical to the “clean” copy of the substitute specification filed on 7 August 2006.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005
tel. (202) 736-8818
fax (202) 736-8711